Phase I trial in Rwanda and South Africa aims to evaluate mRNA HIV vaccine antigen for safety and immunogenicity and strengthen regional scientific capacity
It is part of the company's CAD $30 million capital investment in the Aurora, Canada site
City of Hope is first in world to test oncolytic virus, CF33-hNIS, in people with metastatic solid tumours
A total of three targets have been selected for portfolio entry in the collaboration to date, with the potential to generate further future development milestones and sales-based royalty revenues for BenevolentAI
Moderna continues to expand its mRNA platform for a range of additional clinical applications and routes of administration including a modality for lung delivery
The study will evaluate the effectiveness of Nantheia ATL5, an investigational drug using cannabidiol in ANANDA’s proprietary delivery technology
Potential new treatment for progressive pulmonary fibrosis (PPF) builds on Boehringer Ingelheim’s leadership in lung fibrosis and will be further investigated in a phase III clinical trial program
The drug will be available in 600 hospitals and 105 DTPs
They are GQ1005, an ADC with an excellent bystander killing effect, and GQ1007, a first-in-class antibody-immune-agonist-conjugate (AIAC) both with global intellectual property rights
It is developing the drug candidate to potentially treat immunological diseases
Tirzepatide is primarily indicated for the treatment of T2D and is expected to receive its decision from the FDA in Q2 2022
The median progression free survival, increased from 19.2 months to 35.7 months when Sarclisa was added to carfilzomib and dexamethasone
Boehringer Ingelheim continues to innovate to enhance the customer experience and improve animal health and well-being
Capabilities include the latest in sterile lyophilization and liquid filling technology to support global pharmaceutical supply chain, keeping pace with industry trends
The treatment of chorea associated with HD is within the scope of this Orphan Drug Designation
AKS-452 is currently undergoing Phase II/III clinical testing in India as a primary vaccine; submission for Emergency Use Authorization (EUA) expected by Q3 2022
Image and data analysis of rich spatial information from mIF images can accelerate tissue biomarker discovery and validation
NextSWAB is currently optimized for nasal sample collection with validation for other sample types ongoing
CB03 is a candidate drug for the treatment of refractory epilepsy, independently developed by Zhimeng
The cloud platform will empower biotech companies and CROs with an integrated solution for clinical data management and is supported by Emmes specialist data management teams
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)
